Item 1.01. Entry into Material Definitive Agreement
On February 21,2020, Adamis Pharmaceuticals Corporation (the "Company") entered
into a Securities Purchase Agreement (the "Purchase Agreement") with certain
accredited institutional investors (the "Purchasers") pursuant to which the
Company agreed to issue to the Purchasers, in a registered direct offering and
concurrent private placement, 11,600,000 shares (the "Shares") of the Company's
common stock, par value $0.0001 per share ("Common Stock"), and warrants to
purchase 8,700,000 shares of Common Stock (the "Warrants") with an exercise
price of $0.70 per share. The negotiated combined purchase price for one Share
and 0.75 Warrant will be $0.58. The Company expects to receive aggregate gross
proceeds in the offering of approximately $6,700,000, before deducting fees to
the placement agent and other estimated offering expenses payable by the
Company. The Shares are being offered by the Company pursuant to an effective
shelf registration statement on Form S-3 (Registration No. 333-226100) filed
with the Securities and Exchange Commission (the "SEC") on July 9, 2018 and
declared effective by the SEC on July 18, 2018 (the "Registration Statement"),
as supplemented by a prospectus supplement. The Warrants and the shares of
Common Stock issuable upon exercise of the Warrants (the "Warrant Shares") were
issued in a concurrent private placement and have not been registered under the
Securities Act of 1933, as amended (the "Securities Act"), and are instead being
offered pursuant to the exemption provided in Section 4(a)(2) under the
Securities Act and Rule 506(b) promulgated thereunder. The Warrants will be
exercisable commencing on the later of (i) six months from the date of issuance
or (ii) the date that the Company's stockholders approve a reverse stock split
or an increase in the number of authorized shares of Common Stock of the Company
in an amount sufficient to permit the exercise in full of all of the Warrants
(each, a "Capital Event"), and will expire five years after they become
exercisable. The Securities Purchase Agreement contains customary
representations, warranties and agreements by us and customary conditions to
closing. The closing of the offering is expected to take place on February 25,
2020, subject to customary closing conditions.
Pursuant to the terms of the Purchase Agreement, the Company has agreed that it
will not issue (or enter into any agreement to issue) any shares of Common Stock
or Common Stock equivalents and will not file any registration statements, in
each case subject to certain exceptions, until 75 days following the closing of
the offering (and in the case of variable rate securities, until 60 days
following a Capital Event).
The exercise price of the Warrants and the Warrant Shares will be subject to
adjustment in the event of any stock dividends and splits, reverse stock split,
recapitalization, reorganization or similar transaction, as described in the
Warrants. The Warrants will be exercisable on a "cashless" basis in certain
circumstances.
The Company has agreed to file a registration statement to register the resale
of the Warrant Shares following a Capital Event and to use commercially
reasonable efforts to obtain effectiveness of such registration statement. If no
effective registration statement is available to register the Common Stock
issuable upon the exercise of the Warrants, the holders may exercise the
Warrants by means of a "cashless exercise." The Purchasers have agreed not to
resell or distribute the Warrants or the Warrant Shares to the public except
pursuant to an effective registration statement under the Securities Act or an
exemption thereto.
Maxim Group LLC acted as the sole placement agent (the "Placement Agent") on a
"reasonable best efforts" basis, in connection with the offering. A copy of the
Placement Agency Agreement, dated as of February 20, 2020, by and between the
Company and the Placement Agent is attached hereto as Exhibit 10.2 and
incorporated herein by reference (the "Placement Agency Agreement"). Pursuant to
the Placement Agency Agreement, the Placement Agent will be entitled to a cash
fee of 6% of the gross proceeds paid to the Company for the securities sold in
the offering and reimbursement of certain out-of-pocket expenses. The Placement
Agency Agreement contains customary representations, warranties and agreements
by us and customary conditions to closing. We have agreed to indemnify the
Placement Agent against certain liabilities, including liabilities under the
Securities Act, and liabilities arising from breaches of representations and
warranties contained in the Placement Agency Agreement, or to contribute to
payments that the Placement Agent may have to make regarding those liabilities.
The provisions of the Placement Agency Agreement, Securities Purchase Agreement
and Warrants, including the representations and warranties contained therein,
are not for the benefit of any party other than the parties to such agreement
and are not intended as a document for investors or the public to obtain factual
information about the current state of affairs of the parties to that document.
Rather, investors and the public should look to other disclosures contained in
our filings with the SEC.
The foregoing summaries of the offering, the securities to be issued in
connection therewith, the Purchase Agreement, the Placement Agency Agreement and
the Warrants do not purport to be complete and are qualified in their entirety
by reference to the definitive transaction documents, copies of which are
attached hereto as Exhibits 10.1, 10.2 and 4.1, respectively, and are
incorporated herein by reference.
Item 3.02. Unregistered Sales of Equity Securities
Please see the disclosure regarding the Warrants and the Warrant Shares set
forth under Item 1.01, which is incorporated by reference into this Item 3.02.
Item 8.01. Other Events
On February 21, 2020, the Company issued a press release regarding the
transaction described in Item 1.01, a copy of which is attached hereto as
Exhibit 99.1 and incorporated herein by reference.
On February 19, 2020, the Company issued a press release providing an update on
its New Drug Application ("NDA") resubmission process and the Company's recent
Type A meeting with the U.S. Food and Drug Administration ("FDA") regarding its
NDA for its ZIMHI high-dose naloxone injection product for the treatment of
opioid overdose, the FDA's complete response letter ("CRL") previously delivered
to the Company, and the Company's responses to the CRL. A copy of the Company's
press release is attached hereto as exhibit 99.2 and incorporated herein by
reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is filed herewith:
Exhibit Number Description
4.1 Form of Warrant
5.1 Opinion of Weintraub Tobin Chediak Coleman Grodin
10.1 Form of Securities Purchase Agreement
10.2 Placement Agency Agreement
23.1 Consent of Weintraub Tobin Chediak Coleman Grodin (included in
Exhibit 5.1)
99.1 Press Release dated February 21, 2020
99.2 Press Release dated February 19, 2020
© Edgar Online, source Glimpses